Abstract 275P
Background
Current treatment for primary central nervous system lymphoma involves high-dose methotrexate based regimen. In low&middle-income countries like Vietnam, a shortage of drugs and monitoring is common. The present study reports the first experience and preliminary results of 25 patients PCNSL treated with HD-MTX and RTX.
Methods
Following Institutional Review Board approval by Vietnam National Institute for Cancer Control, a prospective study evaluating the treatment of histologically confirmed PCNSL with combined biweekly HD-MTX (8g/m2/dose) and weekly RTX (375 mg/m2/dose) for 8 cycles. Responders received consolidation treatment with 2 additional cycles, followed by maintenance with monthly HD-MTX for up to 12 months. Patients received aggressive hydration infusion to maintain a urine output of ≥ 100 ml/h and a urinary pH of > 7, until serum MTX levels had decreased to ≤ 0.1 µM/l. Serum MTX levels were monitored daily. Leucovorin rescue was initiated 24 h after completion of MTX infusion and administered at 50 mg IV every 6 h for the first 4 doses and then 30 mg IV until serum MTX levels were ≤0.1 µM/l. Leucovorin dosing was increased in cases of slow MTX clearance. The primary end point was radiographic response, and drug-related toxicity and secondary were survival.
Results
From 01/2017 to 12/2018, 25 patients were analysed (13 males and 12 females, median age 58.6). Following a mean of 10,72 cycles, the response rate and CR rate was 88% and 36%. The median PFS was 13 months and the OS has not yet been attained. MTX clearance was achieved by 72h in 198/268 cycles, and by 96h in 92%; 30.9% cycles needed escalation of leucovorin rescue dose. Toxicity: transient transaminitis (72%), mucotitis (59%) and diarhea (61.9%), febrile neutropenia (8%). Pneumonia was observed in 2 patients. 4 patients had renal dysfunction and 2 patient had dialysis.
Conclusions
RTX combined HDMTX for PCNSL is possible in lower-middle income countries like Vietnam but should be done in experienced centers capable of close monitoring serum MTX levels to prevent toxicity. The addition of RTX to HD-MTX in the treatment of PCNSL may increase response rates and prolong PFS. The final results currently in progress will more definitively estimate the survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract